In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 vipivotide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback